ProCE Banner Activity

SAVOIR: Savolitinib vs Sunitinib in MET-Driven Papillary Renal Cell Carcinoma

Slideset Download
Conference Coverage
Savolitinib demonstrated promising improvements in PFS, OS, and response rate with favorable safety outcomes vs sunitinib.

Released: June 01, 2020

Expiration: May 31, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono